Avicenna Alliance Task Forces

International Affairs Working Group APAC Task Force Mission: Nurture a community of collaboration among Regulators, Industry, and Academia in the APAC region to advance in silico methods, best practices, and policies for Regulatory Science and Innovation Research & Technology Working Group Artificial intelligence (AI) Task Force Mission: Engage in all AA activities related to AI Research & Technology Working Group Cancer & In Silico Oncology Task Force Mission: Accelerate, optimize and personalize cancer treatment through the development, clinical validation and clinical translation of in silico methods In Silico Application Working Group Clinical Deployment Task Force Mission: Promote use of in silico medicine from product development to clinical practice In Silico Application Working Group CMC Application Task Force Mission: Promote use of in silico solutions in CMC throughout product lifecycle Policy Development Working Group EMA Collaboration Task Force Mission: Closely collaborate with the European Medicine Agency (EMA) to inform them about the progress of in silico methods and learn about EMA requirements to accept digital evidence International Affairs Working Group Global Harmonization Task Force Mission: Inform and educate regulatory agencies around the world to ensure harmonized adoption of in silico methods Policy Development Working Group Good Simulation Practice (GSP) Task Force Mission: Drafting a Good Simulation Practice document widely recognized and accepted similar to the Good Clinical Practice Research & Technology Working Group Horizon Europe Task Force Mission: Monitor, influence & inform on Horizon Europe Funding In Silico Application Working Group In Silico Liabilities Task Force Mission: Investigate and document the liabilities and responsibilities for software and modeler developer of in silico solutions In Silico Application Working Group Nonclinical Application Task Force Mission: Promote use of in silico solutions to conduct smarter (3R’s) nonclinical studies Policy Development Working Group Notified Bodies (NB) Task Force Mission: Systematic engagement with NBs to advance in silico trials in Europe Policy Development Working Group Pharmaceutical Strategy (Pharma) Task Force Mission: Accelerate Adoption by Healthcare Stakeholders of In Silico Medicine for Bringing New Medicine to Patients Policy Development Working Group Public & Patient Involvement (PPI) Task Force Mission: Empower the public & patients to understand the potential of in silico medicine, improve healthcare creating ‘user demand’, encourage greater funding and drive broader clinical and regulatory adoption for enhanced impact Research & Technology Working Group Tissue Characterization Task Force Mission: Create a data base of biological tissue properties with Certificate of Birth International Affairs Working Group UK In Silico Regulatory Innovation Task Force Mission: Nurture a cross-sector UK in silico trials community for regulatory science & innovation to produce evidence and harmonize standards in the UK accelerating in silico adoption in regulations